Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN2 | P17706 | 9/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 9/20 | 0.51 |
| ▸ | PTPN5 | P54829 | 9/20 | 0.51 |
| ▸ | AGPAT2 | O15120 | 4/20 | 0.50 |
| ▸ | FBP1 | P09467 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.47 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | SGK1 | O00141 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3130780 | 0.89 | PTPN2 (0.54) | PTPN2PTPN1PTPN5FBP1MAPT | |
| SCHEMBL3136349 | 0.83 | MAPT (0.62) | AGPAT2MAPTTP53 | |
| SCHEMBL4519979 | 0.80 | FBP1 (0.69) | PTPN2PTPN1PTPN5AGPAT2FBP1 | |
| SCHEMBL3127392 | 0.77 | RAB9A (0.57) | AGPAT2MAPTMEN1HTTKMT2A | |
| SCHEMBL3130830 | 0.75 | NPC1 (0.55) | AGPAT2MAPT | |
| SCHEMBL616005 | 0.72 | FBP1 (0.65) | PTPN2PTPN1PTPN5FBP1MAPT | |
| SCHEMBL4509303 | 0.69 | AGPAT2 (0.59) | PTPN2PTPN1PTPN5AGPAT2MAPT | |
| SCHEMBL31701025 | 0.68 | PTPN1 (1.00) | PTPN2PTPN1PTPN5HSPD1HSPE1 | |
| SCHEMBL7258449 | 0.67 | AGPAT2 (1.00) | AGPAT2MAPTTP53 | |
| SCHEMBL2242010 | 0.67 | NPC1 (0.77) | AGPAT2MAPTLMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004301-A1 | Benzoxazoles Useful in the Treatment of Inflammation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004301-A1 | Benzoxazoles Useful in the Treatment of Inflammation | IL4I1, EPX, IL4 | PTPN2 1921/4885PTPN1 1997/4885PTPN5 1972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.